PATIENT PRESELECTION FOR NEW DRUGS
It is often very difficult for a new cancer drug to be established on the clinical market. Cancer treatment protocols are very rigid and need a huge number of validated patient data prior to entering the clinical routine protocols. New drugs are usually over performing but having small number of patient performance history. It is a paradox which is unfortunately difficult to unlock. To develop a new drug is always a massive investment for every pharmaceutical company therefore market penetration is a key question.
QantaScope HexascopeHAEMA™ and iVV assay™ can be used as an in vitro diagnostic tool for patient selection even for new drugs. Finishing clinical phase III studies, where enough data is supporting the new molecules efficacy, finding the right patient for therapy can still be the most burdensome task. Insurance companies and healthcare centers are often too cautious in financing a new player on the market.
Everybody benefits therefore if the introduction of a new diagnostic assay can guide the individualized cancer care. It is common for targeted therapies to perform specific molecular diagnostic tests for patient selection. QantaScope’s iVV assay™ custom designed kits allows that even not targeted medications can be screened before a therapy is applied. It gives a unique opportunity for every new cancer medicine to enter the market and find the right patient who is sensitive for the therapy. The method is very cost effective and increase survival rate drastically.
Please contact our clinical trial team for further information and quotation.